Cognitive, behavioural and sleep-related adverse effects on introduction of levetiracetam versus oxcarbazepine for epilepsy
| Autor: | Kameshwar Prasad, Garima Shukla, Mamta Singh, Roopa Rajan, Deepti Vibha, A. Thelengana, Anupama Gupta, Achal Kumar Srivastava, Awadh Kishor Pandit |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Sleep Wake Disorders 0301 basic medicine medicine.medical_specialty Levetiracetam Trail Making Test Oxcarbazepine Neuropsychological Tests Irritability Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Longitudinal Studies Effects of sleep deprivation on cognitive performance Prospective cohort study Adverse effect Psychiatric Status Rating Scales Epilepsy business.industry Mental Disorders Cross-Sectional Studies 030104 developmental biology Neurology Digit symbol substitution test Anticonvulsants Female Neurology (clinical) medicine.symptom Cognition Disorders business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Epilepsy Research. 150:58-65 |
| ISSN: | 0920-1211 |
| DOI: | 10.1016/j.eplepsyres.2019.01.004 |
| Popis: | Objective There is limited literature on cognitive, behaviour and sleep-related adverse effects of levetiracetam and oxcarbazepine among adult epilepsy patients, except for what is available from the initial efficacy trials. This study was initiated with the aim to evaluate the incidence and prevalence of various cognitive, behaviour and sleep-related adverse effects of levetiracetam versus oxcarbazepine among people with epilepsy. Methods The study was conducted in two parts: part A was a cross-sectional study, and part B was a longitudinal study. Trail making test A & B, digit symbol substitution test, Stroop colour and word test, controlled oral word association test and PGI memory scale, Neuropsychiatric Inventory, sleep log and ESS-I were used for assessment of cognitive, behaviour and sleep-related adverse effects. Results In the cross-sectional as well as prospective study, no significant difference was observed in the cognitive performance of patients in levetiracetam and oxcarbazepine group in any of the cognitive assessment. Among 120 patients enrolled in the cross-sectional study, significantly higher number of patients in the levetiracetam group compared to the oxcarbazepine group,had agitation/aggression (20% vs10%, p = 0.047) and irritability (26.7% vs 3.3%, p = 0.007).Among 132 patients enrolled in the prospective study, significantly higher increase in the domain score of agitation/aggression (14.5% vs 1.6%, p = 0.028) and irritability (17.7% vs 1.6%, p = 0.018) was observed in the levetiracetam group compared to oxcarbazepine group. A significantly higher proportion of patients in the oxcarbazepine group had hypersomnolence (11.3% vs 1.6%, p = 0.026), as compared to the levetiracetam group. Significance On cross-sectional as well as on longitudinal assessment, nearly one-fifth of patients on levetiracetam have behaviour related adverse effects, with dose modification required for half among these. Nearly 11% of patients on oxcarbazepine reported sleep-related adverse effects (higher total sleep duration per 24 h). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect